Atom Investors’s ProQR Therapeutics PRQR Stock Holding History

Atom Investors’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24.4K	Hold	13,107	–	–	﹤0.01%	816
2026 Q1	$21.2K	Hold	13,107	–	–	﹤0.01%	641
2025 Q4	$26.5K	Hold	13,107	–	–	﹤0.01%	552
2025 Q3	$27.9K	Hold	13,107	–	–	﹤0.01%	581
2025 Q2	$26.7K	Hold	13,107	–	–	﹤0.01%	584
2025 Q1	$17.4K	Hold	13,107	–	–	﹤0.01%	485
2024 Q4	$34.7K	Hold	13,107	–	–	﹤0.01%	476
2024 Q3	$23.9K	Hold	13,107	–	–	﹤0.01%	454
2024 Q2	$21.8K	Hold	13,107	–	–	﹤0.01%	455
2024 Q1	$30K	Hold	13,107	–	–	﹤0.01%	547
2023 Q4	$26K	Hold	13,107	–	–	﹤0.01%	437
2023 Q3	$17K	Hold	13,107	–	–	﹤0.01%	420
2023 Q2	$21.2K	Hold	13,107	–	–	0.01%	278
2023 Q1	$27.9K	Sell	13,107 -5,415	-29%	-$16.6K	0.02%	241
2022 Q4	$68.5K	Sell	18,522 -10,299	-36%	-$13.5K	0.03%	201
2022 Q3	$21K	Sell	28,821 -1,601	-5%	-$1.29K	0.01%	271
2022 Q2	$24K	Hold	30,422	–	–	0.01%	245
2022 Q1	$28K	Buy	+30,422	New	+$102K	0.01%	184

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Atom Investors's PRQR Position: Q2 2026 in Review

Atom Investors held its ProQR Therapeutics (PRQR) position steady in Q2 2026 at 13,107 shares worth $24.4K. The position accounts for ﹤0.01% of the portfolio, ranked #816.

Atom Investors first reported a position in PRQR in Q1 2022 and has held it in 18 quarters since. The position peaked at $68.5K in Q4 2022. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

Atom Investors held 13,107 shares of ProQR Therapeutics worth $24.4K as of Q2 2026.
Atom Investors left its ProQR Therapeutics share count unchanged in Q2 2026.
ProQR Therapeutics made up ﹤0.01% of Atom Investors's portfolio in Q2 2026, its #816 holding.
Atom Investors first reported a position in ProQR Therapeutics in Q1 2022 and has held it in 18 quarters since.
Atom Investors's ProQR Therapeutics position peaked at $68.5K in Q4 2022.
70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Atom Investors's 13F filing for Q2 2026, filed 14 Aug 2026.